Galapagos Stock Forecast, Price & News

Galapagos (NASDAQ:GLPG) Frequently Asked Questions

Is Galapagos a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos or view top-rated stocks.

How has Galapagos' stock price been impacted by Coronavirus?

Galapagos' stock was trading at $186.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GLPG shares have decreased by 70.3% and is now trading at $55.19.
View which stocks have been most impacted by COVID-19.

Are investors shorting Galapagos?

Galapagos saw a decrease in short interest in the month of December. As of December 31st, there was short interest totaling 409,700 shares, a decrease of 42.9% from the December 15th total of 717,800 shares. Based on an average daily volume of 235,600 shares, the short-interest ratio is currently 1.7 days. Approximately 0.6% of the shares of the company are sold short.
View Galapagos' Short Interest.

When is Galapagos' next earnings date?

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Galapagos.

How were Galapagos' earnings last quarter?

Galapagos NV (NASDAQ:GLPG) posted its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($1.17) EPS for the quarter, beating the Zacks' consensus estimate of ($1.67) by $0.50. The biotechnology company had revenue of $75.69 million for the quarter, compared to the consensus estimate of $95.17 million. Galapagos had a negative trailing twelve-month return on equity of 7.81% and a negative net margin of 36.28%.
View Galapagos' earnings history.

What price target have analysts set for GLPG?

10 equities research analysts have issued 1-year price targets for Galapagos' stock. Their forecasts range from $50.00 to $125.00. On average, they anticipate Galapagos' stock price to reach $79.47 in the next twelve months. This suggests a possible upside of 44.0% from the stock's current price.
View analysts' price targets for Galapagos or view top-rated stocks among Wall Street analysts.

Who are Galapagos' key executives?

Galapagos' management team includes the following people:

• Onno van de Stolpe, Chief Executive Officer
• Bart Filius, President & Chief Operating Officer
• Piet Wigerinck, Chief Scientific Officer
• Walid Abi-Saab, Chief Medical Officer
• Andre Hoekema, Chief Business Officer

What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Galapagos' key competitors?

Some companies that are related to Galapagos include Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Organon & Co. (OGN), Biohaven Pharmaceutical (BHVN), Maravai LifeSciences (MRVI), Evotec (EVTCY), Ascendis Pharma A/S (ASND), Mirati Therapeutics (MRTX) and Legend Biotech (LEGN).
View all of GLPG's competitors.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

How do I buy shares of Galapagos?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $55.19.

How much money does Galapagos make?

Galapagos has a market capitalization of $3.62 billion and generates $605.66 million in revenue each year.

How many employees does Galapagos have?

Galapagos employs 1,304 workers across the globe.

What is Galapagos' official website?

The official website for Galapagos is www.glpg.com.

Where are Galapagos' headquarters?

Galapagos is headquartered at GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at (321) 534-2900, via email at [email protected], or via fax at 321-534-2901.